deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT04126473

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele

A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose Levels of Subcutaneously Administered ELX-02 in Patients With Cystic Fibrosis With at Least One G542X Allele

Sponsor: Eloxx Pharmaceuticals, Inc.

Conditions Cystic Fibrosis
Interventions ELX-02 Ivacaftor
Updated 19 times since 2019 Last updated: Aug 17, 2023 Started: Nov 5, 2019 Primary completion: Apr 6, 2022 Completion: Apr 6, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cystic Fibrosis and is currently completed. Eloxx Pharmaceuticals, Inc. leads this study, which shows 19 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Sep 2020 · 5 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~Aug 2023 · 16 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Sep 2023 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Unknown Status → Completed

  4. Aug 2023 — Sep 2023 [monthly]

    Unknown Status PHASE2

    Status: Recruiting → Unknown Status

  5. Apr 2022 — Aug 2023 [monthly]

    Recruiting PHASE2

▶ Show 14 earlier versions

  1. Dec 2021 — Apr 2022 [monthly]

    Recruiting PHASE2

  2. Sep 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  3. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  4. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE2

  5. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  6. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  7. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  8. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  9. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  10. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  11. Apr 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  12. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  13. Jan 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  14. Nov 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eloxx Pharmaceuticals, Inc.
Data source: Eloxx Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations